Barrington Research Reaffirms “Outperform” Rating for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE)‘s stock had its “outperform” rating reiterated by analysts at Barrington Research in a note issued to investors on Monday,Benzinga reports. They currently have a $93.00 price objective on the medical instruments supplier’s stock. Barrington Research’s target price points to a potential upside of 43.80% from the stock’s current price.

HAE has been the subject of several other reports. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. CJS Securities raised Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. upped their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Finally, Mizuho lifted their target price on shares of Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Stock Performance

NYSE:HAE opened at $64.67 on Monday. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. The stock’s 50-day simple moving average is $77.88 and its 200 day simple moving average is $65.27. The firm has a market capitalization of $3.03 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.28.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the prior year, the business earned $1.12 earnings per share. The business’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, analysts anticipate that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 11.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 152 shares during the period. GAMMA Investing LLC grew its holdings in Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 165 shares during the period. Central Pacific Bank Trust Division grew its holdings in Haemonetics by 2.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after acquiring an additional 188 shares during the period. Verdence Capital Advisors LLC raised its position in shares of Haemonetics by 3.6% in the 2nd quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier’s stock worth $464,000 after acquiring an additional 214 shares in the last quarter. Finally, Retirement Systems of Alabama lifted its stake in shares of Haemonetics by 0.4% in the 2nd quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock valued at $4,581,000 after purchasing an additional 256 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.